The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous Carcinoma

Exploration of the Treatment Trajectory and Drug Resistance Mechanism of Immunotherapy Combined With Chemotherapy in Patients With Advanced Lung Squamous Carcinoma

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06647836

Enrollment

1000

Registered

2024-10-18

Start date

2021-01-01

Completion date

2027-12-31

Last updated

2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous Cell Lung Cancer

Brief summary

The aim of this observational study is to investigate the treatment trajectory of immunotherapy in patients with squamous non-small cell lung cancer (sq-NSCLC). The primary objective is to identify potential indicators that can predict the efficacy of immunotherapy and explore strategies to prolong its effectiveness in sq-NSCLC patients. Biological specimens and medical imaging data will be collected from patients already receiving immunotherapy as a first-line treatment, and follow-up will be conducted to analyze prognosis based on different patterns.

Detailed description

The medical imaging data will be collected retrospectively and prospectively and the blood samples and tumor tissues will be collected prospectively.

Interventions

OTHEREfficacy observation

Observation about the efficacy of sq-NSCLC patients receiving immunotherapy combined with or without chemotherapy as first-line treatment.

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Diagnosed with sq-NSCLC; * Receiving immunotherapy combined with or without chemotherapy as first-line treatment; * ≥ 18 years and ≤ 80 years old; * No previous treatment in the lungs or any other organ.

Exclusion criteria

* History of cancer treatment; * History of other malignant tumors; * Irregular treatment or poor compliance; * Incomplete clinical information or lost to follow-up.

Design outcomes

Primary

Measure	Time frame	Description
progression-free survival	A two-year period after starting treatment (Regular follow-up every three months after receiving immunotherapy combined with or without chemotherapy as first-line treatment)	The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1.

Secondary

Measure	Time frame	Description
Overall survival	A three-year period after starting treatment (Regular follow-up every six months after receiving immunotherapy combined with or without chemotherapy as first-line treatment)	The survival time aftering receiving immunotherapy combined with or without chemotherapy as first-line treatment.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026